Date: 2014-04-11
Type of information: Collaboration agreement
Compound: ThioBridge™ antibody drug conjugate (ADC)
Company: PolyTherics (UK) MacroGenics (USA - MD)
Therapeutic area: Technology - Services
Type agreement:
Action mechanism:
Disease:
Details: * On April 11, 2014, PolyTherics, a provider of technologies and services to enable the development of better biopharmaceuticals, has announced an extension to its ThioBridge™ antibody drug conjugate (“ADC”) collaboration with MacroGenics, a US biotechnology company developing innovative medicines utilizing its next generation antibody technologies. PolyTherics has developed ThioBridge™ for site-specific conjugation of cytotoxic payloads to antibodies to provide more stable and less heterogeneous ADCs. MacroGenics has two antibody technology platforms, a Dual-Affinity Re-Targeting (DART™) bi-specific platform, in which a single recombinant molecule is able to target two different antigens, and Fc-optimized antibodies with improved effector function. The collaboration was extended following the successful outcome of a research programme undertaken in 2013 under a Research Collaboration and Option Agreement, in which ThioBridge™ was used to conjugate a cytotoxic payload to a range of DART antibodies. MacroGenics and PolyTherics will collaborate in the application of its ThioBridge™ technology to a number of product candidates derived from MacroGenics’ antibody platforms. MacroGenics has an option to licence the ThioBridge™ technology for the development of these product candidates and PolyTherics would receive development milestones and a single-digit percentage royalty on sales of any ThioBridge™ ADC derived from this collaboration.
Financial terms:
Latest news:
